Premarket gainers: NPSP +11%. CTIC +9%. STM +8%.Losers: AEZS -24%. AMD -11%. INFY -7%.

Premarket gainers: NPSP +11%. CTIC +9%. STM +8%.
Losers: AEZS -24%. AMD -11%. INFY -7%.
From other sites
Comments (1)
  • bonifax
    , contributor
    Comments (36) | Send Message
    Capitalization: 108,835,924


    AFTER the CONVERSION of the REMAINING PREFERENCE SHARES equivalent to 18,400 13,156,000 ORDINARY SHARES, the TOTAL NUMBER of SHARES would be 105,024,839 which, at CURRENT PRICE of 1,187€ COMPORTEREBE
    A capitalization of 124,664,448 €.
    CONSIDERING a CASE about (19.000.0 + 56,000,000) $ = $ 75,000,000 EQUAL APPROXIMATELY to 57,692,000 €
    CAPITALIZATION-DEDUCTING that AMOUNT FROM the VALUE of the company would be $ 66,972,448.
    According to the last there would be about 8,000 patients a year interested in spending Pixuvri average of 28,000 € each for a total amount of $ 224,000,000.
    Assuming a 50% of expenditure for the production for marketing you should have an annual return of $ 112,000,000.Leaving aside some cash for Opaxio-orphan-drug in the u.s., may be compounding so low?.
    18 Oct 2012, 08:56 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs